Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute said FDA review of Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism remains ongoing. The open-label extension has maintained high participation and shown indicators of improved glycemic control, including reduced use of background standard-of-care therapies. Enrollment continues in the Phase 3 upLIFT study in tumor-related hyperinsulinism, with topline results still expected before year-end 2026.

Analysis

RZLT’s near-term value is dominated by regulatory interpretation rather than incremental clinical evidence. Open-label reductions in concomitant therapy are directionally encouraging but are not a reliable efficacy or durability read-through without patient-level discontinuation rates, hypoglycemia-event definitions, and exposure-adjusted safety; the market should not capitalize these observations as a label-expansion probability increase. The critical missing variable is whether FDA feedback identifies a resolvable data-package issue versus requests for additional controlled evidence, which creates a binary repricing risk on any agency update over the next 1-3 months.

If approved, a disease-modifying chronic therapy could displace portions of generic diazoxide and higher-burden supportive management, with commercial value determined more by payer recognition of reduced hospitalizations and caregiver burden than by the ultra-rare population count alone. That reimbursement proof will take 6-18 months and may constrain initial uptake if the label, dosing burden, or monitoring requirements are narrower than investors expect. The ongoing pivotal readout in a second population is a separate late-2026 catalyst, but it should not be used to bridge near-term regulatory uncertainty.

Consensus may overvalue the high participation rate in the extension study: retention can reflect lack of alternatives and does not establish comparative benefit. Conversely, a modest delay without a request for new efficacy work could be an opportunity if the stock sells off as though approval odds have structurally broken; the distinction between timing and evidentiary deficiency is the trade-defining fact. Liquidity, cash runway through the regulatory process, manufacturing readiness, and any FDA correspondence remain essential missing diligence items.

Key Decisions for Investors

• Maintain RZLT as a watch-item rather than add directional exposure before a disclosed FDA decision timeline or substantive agency feedback; the press-release update does not independently improve approval probability.
• For portfolios able to tolerate binary biotech risk, consider a small, defined-loss RZLT long only after confirming cash runway extends at least 12 months beyond a potential launch and that no new pivotal-study request has been made. Size for a 40-60% drawdown on adverse regulatory news; upside requires an approvable package plus credible launch financing.
• Use any sharp selloff caused solely by an administrative review extension to initiate a tactical 1-3 month long, but only if management explicitly confirms no request for additional controlled efficacy data. Exit if FDA requires a new trial, requests materially longer follow-up, or the company guides to dilutive financing before resolution.
• Do not pair RZLT against broad biotech ETFs such as XBI: the idiosyncratic regulatory binary will dominate beta. Hedge sector exposure separately if needed, while preserving the company-specific catalyst.